UNITY Biotechnology, Inc. Reports Third Quarter 2024 Financial Results and Business Updates
UNITY Biotechnology [UBX] reported Q3 2024 financial results, highlighting progress in developing UBX1325 (foselutoclax) for diabetic macular edema (DME). Following FDA interaction, UNITY expects a pivotal study to be a non-inferiority trial comparing UBX1325 to aflibercept. Financial highlights include cash position of $29.0 million as of September 30, 2024, net loss of $6.5 million (down from $14.8 million in Q3 2023), and reduced R&D expenses of $2.8 million (down from $4.6 million). The company expects topline 24-week data in Q1 2025 and 36-week data in Q2 2025.
UNITY Biotechnology [UBX] ha riportato i risultati finanziari del terzo trimestre del 2024, evidenziando i progressi nello sviluppo di UBX1325 (foselutoclax) per l'edema maculare diabetico (DME). Dopo l'interazione con la FDA, UNITY prevede che uno studio cruciale sia un trial di non inferiorità che confronterà UBX1325 con aflibercept. Risultati finanziari includono una posizione di cassa di 29,0 milioni di dollari al 30 settembre 2024, una perdita netta di 6,5 milioni di dollari (in calo rispetto ai 14,8 milioni di dollari del Q3 2023) e spese di R&S ridotte a 2,8 milioni di dollari (in calo dai 4,6 milioni). L'azienda prevede dati preliminari a 24 settimane nel Q1 2025 e dati a 36 settimane nel Q2 2025.
UNITY Biotechnology [UBX] informó los resultados financieros del tercer trimestre de 2024, destacando los avances en el desarrollo de UBX1325 (foselutoclax) para el edema macular diabético (DME). Tras la interacción con la FDA, UNITY espera que un estudio pivotal sea un ensayo de no inferioridad que compare UBX1325 con aflibercept. Aspectos financieros incluyen una posición de efectivo de 29,0 millones de dólares al 30 de septiembre de 2024, una pérdida neta de 6,5 millones de dólares (decremento respecto a los 14,8 millones de dólares del Q3 2023), y gastos en I+D reducidos a 2,8 millones de dólares (bajados de 4,6 millones). La compañía espera datos iniciales a 24 semanas en el Q1 2025 y datos a 36 semanas en el Q2 2025.
UNITY Biotechnology [UBX]는 2024년 3분기 재무 결과를 발표하며 당뇨병 황반부종(DME)을 위한 UBX1325(포셀루토클락스) 개발의 진행 상황을 강조했습니다. FDA와의 상호작용 이후, UNITY는 중요한 연구가 UBX1325와 아플리버셉트를 비교하는 비열등성 시험이 될 것으로 기대하고 있습니다. 재무 하이라이트에는 2024년 9월 30일 기준으로 2,900만 달러의 현금 보유, 650만 달러의 순손실(2023년 3분기 1,480만 달러에서 감소) 및 280만 달러로 감소한 연구개발 비용(460만 달러에서 하락)이 포함됩니다. 이 회사는 2025년 1분기에 24주 데이터, 2025년 2분기에 36주 데이터를 기대하고 있습니다.
UNITY Biotechnology [UBX] a rapporté les résultats financiers du troisième trimestre 2024, soulignant les progrès dans le développement d'UBX1325 (foselutoclax) pour l'œdème maculaire diabétique (DME). Suite à une interaction avec la FDA, UNITY s'attend à ce qu'une étude clé soit un essai de non-infériorité comparant UBX1325 à aflibercept. Points financiers incluent une position de trésorerie de 29,0 millions de dollars au 30 septembre 2024, une perte nette de 6,5 millions de dollars (en baisse par rapport à 14,8 millions de dollars au T3 2023) et des dépenses de R&D réduites à 2,8 millions de dollars (en baisse par rapport à 4,6 millions). La société s'attend à des données préliminaires de 24 semaines au T1 2025 et des données à 36 semaines au T2 2025.
UNITY Biotechnology [UBX] hat die finanziellen Ergebnisse für das dritte Quartal 2024 veröffentlicht und dabei Fortschritte bei der Entwicklung von UBX1325 (Foselutoclax) zur Behandlung von diabetischem Makulaödem (DME) hervorgehoben. Nach der Interaktion mit der FDA erwartet UNITY, dass eine zentrale Studie ein Nichtunterlegenheitsstudie sein wird, die UBX1325 mit Aflibercept vergleicht. Finanzielle Highlights umfassen einen Kassenstand von 29,0 Millionen US-Dollar zum 30. September 2024, einen Nettoverlust von 6,5 Millionen US-Dollar (ein Rückgang von 14,8 Millionen US-Dollar im Q3 2023) und reduzierte F&E-Ausgaben von 2,8 Millionen US-Dollar (von 4,6 Millionen US-Dollar gesenkt). Das Unternehmen erwartet in Q1 2025 erste Daten nach 24 Wochen und in Q2 2025 Daten nach 36 Wochen.
- Net loss decreased significantly from $14.8M to $6.5M year-over-year
- Operating expenses reduced with R&D costs down by $1.8M and G&A expenses down by $0.5M
- Cash burn rate improved with $15.0M used in operations vs $29.5M in previous year
- Cash position declined from $43.2M to $29.0M since December 2023
- Current cash runway only extends into Q3 2025
Insights
The Q3 2024 results reveal concerning financial metrics for UNITY Biotechnology.
The company's cash runway extends only into Q3 2025, which may be insufficient to fully support the ongoing Phase 2b ASPIRE study through completion and potential pivotal trial initiation. The reduced R&D spending of
The Phase 2b ASPIRE study design for UBX1325 shows strategic positioning against aflibercept, the current standard of care in DME. The FDA's guidance for a non-inferiority trial with a 4-letter margin on the ETDRS scale provides a clear regulatory pathway. However, the timeline for topline data extending into Q1 2025 puts pressure on the company's cash reserves.
The novel senolytic mechanism of UBX1325 could address significant unmet needs in DME treatment, particularly regarding treatment burden and sub-optimal responses. Yet, the reduction in R&D spending may impact the depth and scope of clinical development activities, potentially affecting the robustness of trial execution.
SOUTH SAN FRANCISCO, Calif., Nov. 04, 2024 (GLOBE NEWSWIRE) -- UNITY Biotechnology, Inc. (UNITY) [NASDAQ:UBX], a biotechnology company developing therapeutics to slow, halt, or reverse diseases of aging, today reported financial results for the third quarter ended September 30, 2024.
“As recently discussed on our Ophthalmology Day for investors and analysts, diabetic macular edema represents a large underserved market due to inadequate response to anti-VEGF standard of care, continued vision loss over time despite treatment, and high treatment burden leading to discontinuation,” said Anirvan Ghosh, Ph.D., chief executive officer of UNITY. “We believe that UBX1325 (foselutoclax) with its novel mechanism of action has the potential to improve long-term visual outcomes for DME patients, via a proven and safe intravitreal route of administration. We believe that the readouts from the Phase 2b ASPIRE study comparing UBX1325 to the aflibercept standard of care will provide a definitive dataset to inform the design of a potential pivotal study.”
In the third quarter of 2024, UNITY had a Type C interaction with the U.S. Food and Drug Administration, or FDA, regarding the development of UBX1325 (foselutoclax) for DME. Based on that interaction, UNITY expects that a pivotal study would need to be a non-inferiority trial comparing UBX1325 to an approved anti-VEGF agent such as aflibercept. The endpoint for regulatory approval is expected to be an assessment of best-corrected visual acuity (BCVA), as assessed by the ETDRS scale with a non-inferiority margin of 4 letters.
The webcast presentation from the Company’s Ophthalmology Investor and Analyst Day is available here.
UBX1325 (foselutoclax) is designed as a novel and durable therapeutic option in diabetic macular edema (DME) that acts via a senolytic mechanism of action, with the potential to address shortcomings of the current standard of care, such as high treatment burden and sub-optimal response to treatment.
UNITY expects topline 24-week primary endpoint data in the first quarter of 2025 and 36-week data in the second quarter of 2025. The Phase 2b ASPIRE study in DME is a multi-center, randomized, double-masked, active-controlled study designed to evaluate the safety and efficacy of UBX1325 in a head-to-head comparison to aflibercept. More information about ASPIRE (NCT06011798) can be found here.
Third Quarter Financial Results
Cash, cash equivalents and marketable securities totaled
Net loss for the three months ended September 30, 2024, was
Research and development expenses decreased by
General and administrative expenses decreased by
About UNITY
UNITY is developing a new class of therapeutics to slow, halt, or reverse diseases of aging. UNITY’s current focus is on creating medicines to selectively eliminate or modulate senescent cells and thereby provide transformative benefit in age-related ophthalmologic and neurologic diseases. More information is available at www.unitybiotechnology.com or follow us on Twitter and LinkedIn.
Forward-Looking Statements
This press release contains forward-looking statements including statements related to UNITY’s understanding of cellular senescence and the role it plays in diseases of aging, the potential for UNITY to develop therapeutics to slow, halt, or reverse diseases of aging, including for ophthalmologic and neurologic diseases, the potential for UNITY to successfully commence and complete clinical studies of UBX1325 for DME, AMD, and other ophthalmologic diseases, the expected timing of enrollment and results of the clinical trials in UBX1325, and UNITY’s expectations regarding the sufficiency of its cash runway. These statements involve substantial known and unknown risks, uncertainties, and other factors that may cause our actual results, levels of activity, performance, or achievements to be materially different from the information expressed or implied by these forward-looking statements, including risks related to delay or disruption in the enrollment of patients in clinical trials, risks relating to the uncertainties inherent in the drug development process, and risks relating to UNITY’s understanding of senescence biology. We may not actually achieve the plans, intentions, or expectations disclosed in our forward-looking statements, and you should not place undue reliance on our forward-looking statements. Actual results or events could differ materially from the plans, intentions and expectations disclosed in the forward-looking statements we make. The forward-looking statements in this press release represent our views as of the date of this release. We anticipate that subsequent events and developments will cause our views to change. However, while we may elect to update these forward-looking statements at some point in the future, we have no current intention of doing so except to the extent required by applicable law. You should, therefore, not rely on these forward-looking statements as representing our views as of any date subsequent to the date of this release. For a further description of the risks and uncertainties that could cause actual results to differ from those expressed in these forward-looking statements, as well as risks relating to the business of the Company in general, see UNITY’s most recent Quarterly Report on Form 10-Q for the quarter ended September 30, 2024, filed with the Securities and Exchange Commission on November 4, 2024, as well as other documents that may be filed by UNITY from time to time with the Securities and Exchange Commission.
Unity Biotechnology, Inc. Statements of Operations and Comprehensive Loss (In thousands, except share and per share amounts) | |||||||||||||||
Three Months Ended | Nine Months Ended | ||||||||||||||
September 30, | September 30, | ||||||||||||||
2024 | 2023 | 2024 | 2023 | ||||||||||||
(Unaudited) | (Unaudited) | ||||||||||||||
Operating expenses: | |||||||||||||||
Research and development | $ | 2,787 | $ | 4,632 | $ | 9,971 | $ | 16,828 | |||||||
General and administrative | 3,815 | 4,347 | 11,209 | 14,560 | |||||||||||
Impairment of long-lived assets | — | 5,602 | — | 5,602 | |||||||||||
Total operating expenses | 6,602 | 14,581 | 21,180 | 36,990 | |||||||||||
Loss from operations | (6,602 | ) | (14,581 | ) | (21,180 | ) | (36,990 | ) | |||||||
Interest income | 396 | 689 | 1,424 | 2,349 | |||||||||||
Interest expense | — | (566 | ) | — | (2,451 | ) | |||||||||
Gain (loss) on warrant liability | (215 | ) | 253 | 2,407 | 2,283 | ||||||||||
Other income (expense), net | (60 | ) | (577 | ) | (201 | ) | (711 | ) | |||||||
Net loss | (6,481 | ) | (14,782 | ) | (17,550 | ) | (35,520 | ) | |||||||
Other comprehensive gain (loss) | |||||||||||||||
Unrealized gain (loss) on marketable debt securities | 74 | 81 | 63 | 196 | |||||||||||
Comprehensive loss | $ | (6,407 | ) | $ | (14,701 | ) | $ | (17,487 | ) | $ | (35,324 | ) | |||
Net loss per share, basic and diluted | $ | (0.38 | ) | $ | (1.01 | ) | $ | (1.04 | ) | $ | (2.46 | ) | |||
Weighted-average number of shares used in computing net loss per share, basic and diluted | 16,849,283 | 14,598,218 | 16,816,706 | 14,446,672 | |||||||||||
Unity Biotechnology, Inc. Condensed Balance Sheets (In thousands) | |||||||
September 30, | December 31, | ||||||
2024 | 2023 | ||||||
(Unaudited) | |||||||
Assets | |||||||
Current Assets: | |||||||
Cash and cash equivalents | $ | 8,898 | $ | 19,803 | |||
Short-term marketable securities | 20,139 | 23,398 | |||||
Prepaid expenses and other current assets | 1,226 | 3,404 | |||||
Total current assets | 30,263 | 46,605 | |||||
Property and equipment, net | 4,414 | 5,082 | |||||
Operating lease right-of-use assets | 11,359 | 12,981 | |||||
Long-term restricted cash | 896 | 896 | |||||
Other long-term assets | 200 | 126 | |||||
Total assets | $ | 47,132 | $ | 65,690 | |||
Liabilities and Stockholders’ Equity | |||||||
Current liabilities: | |||||||
Accounts payable | $ | 1,804 | $ | 1,380 | |||
Accrued compensation | 1,704 | 1,841 | |||||
Accrued and other current liabilities | 5,276 | 4,619 | |||||
Total current liabilities | 8,784 | 7,840 | |||||
Operating lease liability, net of current portion | 20,698 | 23,539 | |||||
Warrant liability | 3,506 | 5,913 | |||||
Total liabilities | 32,988 | 37,292 | |||||
Commitments and contingencies | |||||||
Stockholders’ equity: | |||||||
Common stock | 2 | 2 | |||||
Additional paid-in capital | 516,006 | 512,773 | |||||
Accumulated other comprehensive gain | 39 | (24 | ) | ||||
Accumulated deficit | (501,903 | ) | (484,353 | ) | |||
Total stockholders’ equity | 14,144 | 28,398 | |||||
Total liabilities and stockholders’ equity | $ | 47,132 | $ | 65,690 | |||
Media
Inizio Evoke Comms
Katherine Smith
katherine.smith@inizioevoke.com
Investor Contact
LifeSci Advisors, LLC
Joyce Allaire
jallaire@lifesciadvisors.com
FAQ
What were UNITY Biotechnology's (UBX) Q3 2024 financial results?
When will UBX release topline data for UBX1325 in DME treatment?
What is UBX's cash runway based on Q3 2024 results?